View ValuationBGI Genomics 향후 성장Future 기준 점검 3/6BGI Genomics (는) 각각 연간 117.1% 및 5.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 117.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 1% 로 예상됩니다.핵심 정보117.1%이익 성장률117.14%EPS 성장률Biotechs 이익 성장29.7%매출 성장률5.8%향후 자기자본이익률1.00%애널리스트 커버리지Low마지막 업데이트29 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jun 30BGI Genomics Co., Ltd. to Report First Half, 2026 Results on Aug 22, 2026BGI Genomics Co., Ltd. announced that they will report first half, 2026 results on Aug 22, 2026공고 • Jun 17BGI Genomics Co., Ltd. (SZSE:300676) announces an Equity Buyback for CNY 500 million worth of its shares.BGI Genomics Co., Ltd. (SZSE:300676) announces a share repurchase program. Under the program, the company will repurchase up to CNY 500 million worth of class A shares. The shares will be repurchased at a price of not more than CNY 50 per share. The shares purchased will be used for the company's equity incentive plan or employee stock ownership plans. The program will be funded out of the own funds and self-raised funds (including special loans for stock repurchase from financial institutions. The program will be valid till 12 months from board approval date.Board Change • May 20High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. CFO, Deputy GM & Non Independent Director Yujue Wang was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공고 • Apr 25BGI Genomics Co., Ltd., Annual General Meeting, May 20, 2026BGI Genomics Co., Ltd., Annual General Meeting, May 20, 2026, at 14:30 China Standard Time. Location: Zone C, No. 9, Yunhua Road, Meisha Subdistrict, Yantian District, Shenzhen, Guangdong China공고 • Mar 31BGI Genomics Co., Ltd. to Report Q1, 2026 Results on Apr 25, 2026BGI Genomics Co., Ltd. announced that they will report Q1, 2026 results on Apr 25, 2026공고 • Dec 31BGI Genomics Co., Ltd. to Report Fiscal Year 2025 Results on Apr 25, 2026BGI Genomics Co., Ltd. announced that they will report fiscal year 2025 results on Apr 25, 2026공고 • Sep 30BGI Genomics Co., Ltd. to Report Q3, 2025 Results on Oct 24, 2025BGI Genomics Co., Ltd. announced that they will report Q3, 2025 results on Oct 24, 2025공고 • Sep 23An undisclosed buyer acquired 4% stake in BGI Genomics Co., Ltd. (SZSE:300676) from Shenzhen Huada Gene Technology Co., Ltd. for Approximately CNY 740 million.An undisclosed buyer acquired 4% stake in BGI Genomics Co., Ltd. (SZSE:300676) from Shenzhen Huada Gene Technology Co., Ltd. for Approximately CNY 740 million on September 22, 2025. An undisclosed buyer completed the acquisition of 4% stake in BGI Genomics Co., Ltd. (SZSE:300676) from Shenzhen Huada Gene Technology Co., Ltd. on September 22, 2025.공고 • Jul 02BGI Genomics Co., Ltd. to Report First Half, 2025 Results on Aug 23, 2025BGI Genomics Co., Ltd. announced that they will report first half, 2025 results on Aug 23, 2025공고 • Apr 26BGI Genomics Co., Ltd., Annual General Meeting, May 20, 2025BGI Genomics Co., Ltd., Annual General Meeting, May 20, 2025, at 14:30 China Standard Time. Location: Area C, No. 9, Yunhua Road, Meisha Subdistrict, Yantian District, Shenzhen, Guangdong China공고 • Mar 31BGI Genomics Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025BGI Genomics Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025공고 • Dec 31BGI Genomics Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025BGI Genomics Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025Reported Earnings • Oct 26Third quarter 2024 earnings released: CN¥0.36 loss per share (vs CN¥0.045 profit in 3Q 2023)Third quarter 2024 results: CN¥0.36 loss per share (down from CN¥0.045 profit in 3Q 2023). Revenue: CN¥954.5m (down 11% from 3Q 2023). Net loss: CN¥142.4m (down CN¥161.0m from profit in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.공고 • Sep 30BGI Genomics Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024BGI Genomics Co., Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024Reported Earnings • Aug 24Second quarter 2024 earnings released: EPS: CN¥0.013 (vs CN¥0.027 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.013 (down from CN¥0.027 in 2Q 2023). Revenue: CN¥1.05b (down 6.0% from 2Q 2023). Net income: CN¥5.80m (down 44% from 2Q 2023). Profit margin: 0.6% (down from 0.9% in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 47 percentage points per year, which is a significant difference in performance.Board Change • Jul 18High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CFO, Deputy GM & Non Independent Director Yujue Wang was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공고 • Jun 29BGI Genomics Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024BGI Genomics Co., Ltd. announced that they will report first half, 2024 results on Aug 24, 2024공고 • Jun 28BGI Genomics Co., Ltd. Announces Final Cash Dividend Plan on A Shares for the Year 2023, Payable on 4 July 2024BGI Genomics Co., Ltd. announced 2023 final profit distribution plan to be implemented (A shares): cash dividend of CNY 1.0000000 per ten shares (tax included) for the year 2023. Record date is 3 July 2024. Ex-date is 4 July 2024. Payment date is 4 July 2024.공고 • Jun 20BGI Genomics Co., Ltd. Announces Board AppointmentsBGI Genomics Co., Ltd. announced at the EGM held on June 18, 2024, approved election of Zhu Shida, Zhang Guocheng and Wang Yujue as non-independent director and Hou Zhibo, independent director.공고 • May 11Bgi Genomics Co., Ltd. Approves Cash Dividend for 2023BGI Genomics Co., Ltd. announced at the AGM held on May 9, 2024, approved Cash dividend/10 shares (tax included): CNY 1.00000000 for 2023.Reported Earnings • Apr 14Full year 2023 earnings released: EPS: CN¥0.23 (vs CN¥1.96 in FY 2022)Full year 2023 results: EPS: CN¥0.23 (down from CN¥1.96 in FY 2022). Revenue: CN¥4.35b (down 38% from FY 2022). Net income: CN¥92.9m (down 88% from FY 2022). Profit margin: 2.1% (down from 11% in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 36 percentage points per year, which is a significant difference in performance.공고 • Apr 13BGI Genomics Co., Ltd., Annual General Meeting, May 09, 2024BGI Genomics Co., Ltd., Annual General Meeting, May 09, 2024, at 14:00 China Standard Time.공고 • Mar 30BGI Genomics Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024BGI Genomics Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024New Risk • Mar 01New major risk - Revenue and earnings growthEarnings have declined by 5.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 331% Paying a dividend despite having no free cash flows. Earnings have declined by 5.4% per year over the past 5 years. Minor Risk Profit margins are more than 30% lower than last year (2.1% net profit margin).Reported Earnings • Mar 01Full year 2023 earnings released: EPS: CN¥0.22 (vs CN¥1.96 in FY 2022)Full year 2023 results: EPS: CN¥0.22 (down from CN¥1.96 in FY 2022). Revenue: CN¥4.35b (down 38% from FY 2022). Net income: CN¥91.2m (down 89% from FY 2022). Profit margin: 2.1% (down from 11% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 40 percentage points per year, which is a significant difference in performance.공고 • Dec 29BGI Genomics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 13, 2024BGI Genomics Co., Ltd. announced that they will report fiscal year 2023 results on Apr 13, 2024Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: CN¥0.045 (vs CN¥0.35 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.045 (down from CN¥0.35 in 3Q 2022). Revenue: CN¥1.07b (down 21% from 3Q 2022). Net income: CN¥18.6m (down 87% from 3Q 2022). Profit margin: 1.7% (down from 11% in 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 36 percentage points per year, which is a significant difference in performance.New Risk • Aug 13New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Payout ratio: 167% The company is paying a dividend despite having no free cash flows. Dividend yield: 1.7% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 167% Paying a dividend despite having no free cash flows. High level of non-cash earnings (36% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (4.2% net profit margin).Reported Earnings • Aug 12Second quarter 2023 earnings released: EPS: CN¥0.027 (vs CN¥0.68 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.027 (down from CN¥0.68 in 2Q 2022). Revenue: CN¥1.12b (down 36% from 2Q 2022). Net income: CN¥10.4m (down 96% from 2Q 2022). Profit margin: 0.9% (down from 16% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings.공고 • Jul 01BGI Genomics Co., Ltd. to Report First Half, 2023 Results on Aug 12, 2023BGI Genomics Co., Ltd. announced that they will report first half, 2023 results on Aug 12, 2023공고 • Jun 01Bgi Genomics Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 7 June 2023BGI Genomics Co., Ltd. announced 2022 final profit distribution plan to be implemented (A shares): cash dividend of CNY 10.0000000 per ten shares (tax included) for the year 2022. Record date is 06 June 2023. Ex-date is 07 June 2023. Payment date is 07 June 2023.Reported Earnings • Apr 26First quarter 2023 earnings released: EPS: CN¥0.091 (vs CN¥0.81 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.091 (down from CN¥0.81 in 1Q 2022). Revenue: CN¥953.8m (down 33% from 1Q 2022). Net income: CN¥41.3m (down 88% from 1Q 2022). Profit margin: 4.3% (down from 23% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 30%After last week's 30% share price gain to CN¥75.83, the stock trades at a trailing P/E ratio of 39.2x. Average trailing P/E is 41x in the Biotechs industry in China. Total loss to shareholders of 6.9% over the past three years.Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Ya Cao was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.80 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.35 (down from CN¥0.80 in 3Q 2021). Revenue: CN¥1.35b (down 10% from 3Q 2021). Net income: CN¥141.4m (down 57% from 3Q 2021). Profit margin: 11% (down from 22% in 3Q 2021). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 26Second quarter 2022 earnings released: EPS: CN¥20.98 (vs CN¥1.37 in 2Q 2021)Second quarter 2022 results: EPS: CN¥20.98 (up from CN¥1.37 in 2Q 2021). Revenue: CN¥25.7b (up CN¥23.6b from 2Q 2021). Net income: CN¥1.47b (up 162% from 2Q 2021). Profit margin: 5.7% (down from 27% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is expected to shrink by 63% compared to a 33% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: CN¥0.81 (vs CN¥1.29 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.81 (down from CN¥1.29 in 1Q 2021). Revenue: CN¥1.43b (down 8.5% from 1Q 2021). Net income: CN¥330.4m (down 37% from 1Q 2021). Profit margin: 23% (down from 34% in 1Q 2021). The decrease in margin was primarily driven by lower revenue. Over the next year, revenue is expected to shrink by 18% compared to a 44% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Ya Cao was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 28% share price gain to CN¥98.32, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 34x in the Biotechs industry in China. Total returns to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥62.75 per share.Reported Earnings • Feb 28Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: CN¥3.48 (down from CN¥5.25 in FY 2020). Revenue: CN¥6.70b (down 20% from FY 2020). Net income: CN¥1.43b (down 32% from FY 2020). Profit margin: 21% (down from 25% in FY 2020). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 20%. Over the next year, revenue is forecast to grow 17%, compared to a 37% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 28Second quarter 2021 earnings released: EPS CN¥1.37 (vs CN¥3.79 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥2.08b (down 37% from 2Q 2020). Net income: CN¥561.0m (down 63% from 2Q 2020). Profit margin: 27% (down from 46% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.Executive Departure • Aug 11Chairman of Scientific Advisory Board Tadataka Yamada has left the companyOn the 4th of August, Tadataka Yamada's tenure as Chairman of Scientific Advisory Board ended after 5.3 years in the role. We don't have any record of a personal shareholding under Tadataka's name. Tadataka is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 6.17 years.Executive Departure • Aug 05Chairman of Scientific Advisory Board Tadataka Yamada has left the companyOn the 3rd of August, Tadataka Yamada's tenure as Chairman of Scientific Advisory Board ended after 5.3 years in the role. We don't have any record of a personal shareholding under Tadataka's name. Tadataka is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 6.17 years.Valuation Update With 7 Day Price Move • Aug 03Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥114, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 45x in the Biotechs industry in China. Total returns to shareholders of 52% over the past three years.Reported Earnings • Apr 26First quarter 2021 earnings released: EPS CN¥1.29 (vs CN¥0.35 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥1.56b (up 98% from 1Q 2020). Net income: CN¥525.0m (up 275% from 1Q 2020). Profit margin: 34% (up from 18% in 1Q 2020). The increase in margin was driven by higher revenue.Is New 90 Day High Low • Mar 09New 90-day low: CN¥125The company is down 3.0% from its price of CN¥129 on 09 December 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥1.01 per share.Reported Earnings • Mar 04Full year 2020 earnings released: EPS CN¥5.23 (vs CN¥0.69 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥8.43b (up 201% from FY 2019). Net income: CN¥2.08b (up CN¥1.80b from FY 2019). Profit margin: 25% (up from 9.9% in FY 2019). The increase in margin was driven by higher revenue.Analyst Estimate Surprise Post Earnings • Mar 04Revenue misses expectationsRevenue missed analyst estimates by 6.2%. Over the next year, revenue is expected to shrink by 36% compared to a 57% growth forecast for the Biotechs industry in China.Valuation Update With 7 Day Price Move • Jan 28Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥147, the stock is trading at a trailing P/E ratio of 21.6x, down from the previous P/E ratio of 26.2x. This compares to an average P/E of 64x in the Biotechs industry in China. Total returns to shareholders over the past year are 85%.Is New 90 Day High Low • Jan 21New 90-day high: CN¥166The company is up 25% from its price of CN¥133 on 23 October 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥0.93 per share.Valuation Update With 7 Day Price Move • Jan 11Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥148, the stock is trading at a trailing P/E ratio of 21.7x, up from the previous P/E ratio of 18.8x. This compares to an average P/E of 66x in the Biotechs industry in China. Total returns to shareholders over the past year are 117%.Is New 90 Day High Low • Dec 18New 90-day low: CN¥127The company is down 10.0% from its price of CN¥142 on 18 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥1.51 per share.Is New 90 Day High Low • Nov 17New 90-day low: CN¥132The company is down 7.0% from its price of CN¥141 on 19 August 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥1.33 per share.Reported Earnings • Oct 28Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥2.71b, with earnings increasing by CN¥2.38b from the prior year. Total revenue was CN¥7.48b over the last 12 months, up 168% from the prior year.Is New 90 Day High Low • Oct 23New 90-day low: CN¥133The company is down 12% from its price of CN¥151 on 24 July 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥1.22 per share.이익 및 매출 성장 예측XSEC:300676 - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20284,476140N/A806112/31/20274,13067N/A740112/31/20263,885-1N/A68913/31/20263,842-573-356153N/A12/31/20253,705-617-569-63N/A9/30/20253,715-800-639-198N/A6/30/20253,627-915-823-238N/A3/31/20253,718-968-816-225N/A12/31/20243,867-903-43496N/A9/30/20244,032-102-57184N/A6/30/20244,14961-584326N/A3/31/20244,21664-794311N/A12/31/20234,35093-828409N/A9/30/20235,679126-1,189504N/A6/30/20235,964247-1,179358N/A3/31/20236,578514-569827N/A1/1/20237,053803-1,136131N/A9/30/20226,132794-144530N/A6/30/20226,2819811,0861,586N/A3/31/20226,6331,2671,2051,670N/A1/1/20226,7661,4622,0932,476N/A9/30/20216,7977982,4382,759N/A6/30/20217,9361,5231,8812,229N/A3/31/20219,1692,4743,2553,545N/A12/31/20208,3972,0893,3023,603N/A9/30/20207,4802,7122,6022,970N/A6/30/20205,6171,7301,9822,385N/A3/31/20203,00931883712N/A12/31/20192,800276N/A224N/A9/30/20192,795337N/A14N/A6/30/20192,687377N/A-38N/A3/31/20192,603384N/A-131N/A12/31/20182,536387N/A15N/A9/30/20182,463406N/A18N/A6/30/20182,348415N/A138N/A3/31/20182,224404N/A150N/A12/31/20172,096398N/A244N/A9/30/20171,901388N/A145N/A6/30/20171,833375N/A203N/A3/31/20171,796352N/AN/AN/A12/31/20161,711333N/A234N/A6/30/20161,520336N/A296N/A3/31/20161,339299N/AN/AN/A12/31/20151,319262N/A329N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 300676 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(2.4%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: 300676 (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: 300676 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: 300676 의 수익(연간 5.8%)이 CN 시장(연간 16.1%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: 300676 의 수익(연간 5.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 300676의 자본 수익률은 3년 후 1%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/23 23:42종가2026/07/23 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BGI Genomics Co., Ltd.는 4명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Wen DaiHuatai ResearchJiaxi XuIndustrial Securities Co. Ltd.Yuan Yuan SunIndustrial Securities Co. Ltd.1명의 분석가 더 보기
공고 • Jun 30BGI Genomics Co., Ltd. to Report First Half, 2026 Results on Aug 22, 2026BGI Genomics Co., Ltd. announced that they will report first half, 2026 results on Aug 22, 2026
공고 • Jun 17BGI Genomics Co., Ltd. (SZSE:300676) announces an Equity Buyback for CNY 500 million worth of its shares.BGI Genomics Co., Ltd. (SZSE:300676) announces a share repurchase program. Under the program, the company will repurchase up to CNY 500 million worth of class A shares. The shares will be repurchased at a price of not more than CNY 50 per share. The shares purchased will be used for the company's equity incentive plan or employee stock ownership plans. The program will be funded out of the own funds and self-raised funds (including special loans for stock repurchase from financial institutions. The program will be valid till 12 months from board approval date.
Board Change • May 20High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. CFO, Deputy GM & Non Independent Director Yujue Wang was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공고 • Apr 25BGI Genomics Co., Ltd., Annual General Meeting, May 20, 2026BGI Genomics Co., Ltd., Annual General Meeting, May 20, 2026, at 14:30 China Standard Time. Location: Zone C, No. 9, Yunhua Road, Meisha Subdistrict, Yantian District, Shenzhen, Guangdong China
공고 • Mar 31BGI Genomics Co., Ltd. to Report Q1, 2026 Results on Apr 25, 2026BGI Genomics Co., Ltd. announced that they will report Q1, 2026 results on Apr 25, 2026
공고 • Dec 31BGI Genomics Co., Ltd. to Report Fiscal Year 2025 Results on Apr 25, 2026BGI Genomics Co., Ltd. announced that they will report fiscal year 2025 results on Apr 25, 2026
공고 • Sep 30BGI Genomics Co., Ltd. to Report Q3, 2025 Results on Oct 24, 2025BGI Genomics Co., Ltd. announced that they will report Q3, 2025 results on Oct 24, 2025
공고 • Sep 23An undisclosed buyer acquired 4% stake in BGI Genomics Co., Ltd. (SZSE:300676) from Shenzhen Huada Gene Technology Co., Ltd. for Approximately CNY 740 million.An undisclosed buyer acquired 4% stake in BGI Genomics Co., Ltd. (SZSE:300676) from Shenzhen Huada Gene Technology Co., Ltd. for Approximately CNY 740 million on September 22, 2025. An undisclosed buyer completed the acquisition of 4% stake in BGI Genomics Co., Ltd. (SZSE:300676) from Shenzhen Huada Gene Technology Co., Ltd. on September 22, 2025.
공고 • Jul 02BGI Genomics Co., Ltd. to Report First Half, 2025 Results on Aug 23, 2025BGI Genomics Co., Ltd. announced that they will report first half, 2025 results on Aug 23, 2025
공고 • Apr 26BGI Genomics Co., Ltd., Annual General Meeting, May 20, 2025BGI Genomics Co., Ltd., Annual General Meeting, May 20, 2025, at 14:30 China Standard Time. Location: Area C, No. 9, Yunhua Road, Meisha Subdistrict, Yantian District, Shenzhen, Guangdong China
공고 • Mar 31BGI Genomics Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025BGI Genomics Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025
공고 • Dec 31BGI Genomics Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025BGI Genomics Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025
Reported Earnings • Oct 26Third quarter 2024 earnings released: CN¥0.36 loss per share (vs CN¥0.045 profit in 3Q 2023)Third quarter 2024 results: CN¥0.36 loss per share (down from CN¥0.045 profit in 3Q 2023). Revenue: CN¥954.5m (down 11% from 3Q 2023). Net loss: CN¥142.4m (down CN¥161.0m from profit in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.
공고 • Sep 30BGI Genomics Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024BGI Genomics Co., Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024
Reported Earnings • Aug 24Second quarter 2024 earnings released: EPS: CN¥0.013 (vs CN¥0.027 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.013 (down from CN¥0.027 in 2Q 2023). Revenue: CN¥1.05b (down 6.0% from 2Q 2023). Net income: CN¥5.80m (down 44% from 2Q 2023). Profit margin: 0.6% (down from 0.9% in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 47 percentage points per year, which is a significant difference in performance.
Board Change • Jul 18High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CFO, Deputy GM & Non Independent Director Yujue Wang was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공고 • Jun 29BGI Genomics Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024BGI Genomics Co., Ltd. announced that they will report first half, 2024 results on Aug 24, 2024
공고 • Jun 28BGI Genomics Co., Ltd. Announces Final Cash Dividend Plan on A Shares for the Year 2023, Payable on 4 July 2024BGI Genomics Co., Ltd. announced 2023 final profit distribution plan to be implemented (A shares): cash dividend of CNY 1.0000000 per ten shares (tax included) for the year 2023. Record date is 3 July 2024. Ex-date is 4 July 2024. Payment date is 4 July 2024.
공고 • Jun 20BGI Genomics Co., Ltd. Announces Board AppointmentsBGI Genomics Co., Ltd. announced at the EGM held on June 18, 2024, approved election of Zhu Shida, Zhang Guocheng and Wang Yujue as non-independent director and Hou Zhibo, independent director.
공고 • May 11Bgi Genomics Co., Ltd. Approves Cash Dividend for 2023BGI Genomics Co., Ltd. announced at the AGM held on May 9, 2024, approved Cash dividend/10 shares (tax included): CNY 1.00000000 for 2023.
Reported Earnings • Apr 14Full year 2023 earnings released: EPS: CN¥0.23 (vs CN¥1.96 in FY 2022)Full year 2023 results: EPS: CN¥0.23 (down from CN¥1.96 in FY 2022). Revenue: CN¥4.35b (down 38% from FY 2022). Net income: CN¥92.9m (down 88% from FY 2022). Profit margin: 2.1% (down from 11% in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 36 percentage points per year, which is a significant difference in performance.
공고 • Apr 13BGI Genomics Co., Ltd., Annual General Meeting, May 09, 2024BGI Genomics Co., Ltd., Annual General Meeting, May 09, 2024, at 14:00 China Standard Time.
공고 • Mar 30BGI Genomics Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024BGI Genomics Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024
New Risk • Mar 01New major risk - Revenue and earnings growthEarnings have declined by 5.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 331% Paying a dividend despite having no free cash flows. Earnings have declined by 5.4% per year over the past 5 years. Minor Risk Profit margins are more than 30% lower than last year (2.1% net profit margin).
Reported Earnings • Mar 01Full year 2023 earnings released: EPS: CN¥0.22 (vs CN¥1.96 in FY 2022)Full year 2023 results: EPS: CN¥0.22 (down from CN¥1.96 in FY 2022). Revenue: CN¥4.35b (down 38% from FY 2022). Net income: CN¥91.2m (down 89% from FY 2022). Profit margin: 2.1% (down from 11% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 40 percentage points per year, which is a significant difference in performance.
공고 • Dec 29BGI Genomics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 13, 2024BGI Genomics Co., Ltd. announced that they will report fiscal year 2023 results on Apr 13, 2024
Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: CN¥0.045 (vs CN¥0.35 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.045 (down from CN¥0.35 in 3Q 2022). Revenue: CN¥1.07b (down 21% from 3Q 2022). Net income: CN¥18.6m (down 87% from 3Q 2022). Profit margin: 1.7% (down from 11% in 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 36 percentage points per year, which is a significant difference in performance.
New Risk • Aug 13New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Payout ratio: 167% The company is paying a dividend despite having no free cash flows. Dividend yield: 1.7% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 167% Paying a dividend despite having no free cash flows. High level of non-cash earnings (36% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (4.2% net profit margin).
Reported Earnings • Aug 12Second quarter 2023 earnings released: EPS: CN¥0.027 (vs CN¥0.68 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.027 (down from CN¥0.68 in 2Q 2022). Revenue: CN¥1.12b (down 36% from 2Q 2022). Net income: CN¥10.4m (down 96% from 2Q 2022). Profit margin: 0.9% (down from 16% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings.
공고 • Jul 01BGI Genomics Co., Ltd. to Report First Half, 2023 Results on Aug 12, 2023BGI Genomics Co., Ltd. announced that they will report first half, 2023 results on Aug 12, 2023
공고 • Jun 01Bgi Genomics Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 7 June 2023BGI Genomics Co., Ltd. announced 2022 final profit distribution plan to be implemented (A shares): cash dividend of CNY 10.0000000 per ten shares (tax included) for the year 2022. Record date is 06 June 2023. Ex-date is 07 June 2023. Payment date is 07 June 2023.
Reported Earnings • Apr 26First quarter 2023 earnings released: EPS: CN¥0.091 (vs CN¥0.81 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.091 (down from CN¥0.81 in 1Q 2022). Revenue: CN¥953.8m (down 33% from 1Q 2022). Net income: CN¥41.3m (down 88% from 1Q 2022). Profit margin: 4.3% (down from 23% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 30%After last week's 30% share price gain to CN¥75.83, the stock trades at a trailing P/E ratio of 39.2x. Average trailing P/E is 41x in the Biotechs industry in China. Total loss to shareholders of 6.9% over the past three years.
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Ya Cao was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.80 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.35 (down from CN¥0.80 in 3Q 2021). Revenue: CN¥1.35b (down 10% from 3Q 2021). Net income: CN¥141.4m (down 57% from 3Q 2021). Profit margin: 11% (down from 22% in 3Q 2021). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 26Second quarter 2022 earnings released: EPS: CN¥20.98 (vs CN¥1.37 in 2Q 2021)Second quarter 2022 results: EPS: CN¥20.98 (up from CN¥1.37 in 2Q 2021). Revenue: CN¥25.7b (up CN¥23.6b from 2Q 2021). Net income: CN¥1.47b (up 162% from 2Q 2021). Profit margin: 5.7% (down from 27% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is expected to shrink by 63% compared to a 33% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: CN¥0.81 (vs CN¥1.29 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.81 (down from CN¥1.29 in 1Q 2021). Revenue: CN¥1.43b (down 8.5% from 1Q 2021). Net income: CN¥330.4m (down 37% from 1Q 2021). Profit margin: 23% (down from 34% in 1Q 2021). The decrease in margin was primarily driven by lower revenue. Over the next year, revenue is expected to shrink by 18% compared to a 44% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Ya Cao was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 28% share price gain to CN¥98.32, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 34x in the Biotechs industry in China. Total returns to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥62.75 per share.
Reported Earnings • Feb 28Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: CN¥3.48 (down from CN¥5.25 in FY 2020). Revenue: CN¥6.70b (down 20% from FY 2020). Net income: CN¥1.43b (down 32% from FY 2020). Profit margin: 21% (down from 25% in FY 2020). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 20%. Over the next year, revenue is forecast to grow 17%, compared to a 37% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 28Second quarter 2021 earnings released: EPS CN¥1.37 (vs CN¥3.79 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥2.08b (down 37% from 2Q 2020). Net income: CN¥561.0m (down 63% from 2Q 2020). Profit margin: 27% (down from 46% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
Executive Departure • Aug 11Chairman of Scientific Advisory Board Tadataka Yamada has left the companyOn the 4th of August, Tadataka Yamada's tenure as Chairman of Scientific Advisory Board ended after 5.3 years in the role. We don't have any record of a personal shareholding under Tadataka's name. Tadataka is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 6.17 years.
Executive Departure • Aug 05Chairman of Scientific Advisory Board Tadataka Yamada has left the companyOn the 3rd of August, Tadataka Yamada's tenure as Chairman of Scientific Advisory Board ended after 5.3 years in the role. We don't have any record of a personal shareholding under Tadataka's name. Tadataka is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 6.17 years.
Valuation Update With 7 Day Price Move • Aug 03Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥114, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 45x in the Biotechs industry in China. Total returns to shareholders of 52% over the past three years.
Reported Earnings • Apr 26First quarter 2021 earnings released: EPS CN¥1.29 (vs CN¥0.35 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥1.56b (up 98% from 1Q 2020). Net income: CN¥525.0m (up 275% from 1Q 2020). Profit margin: 34% (up from 18% in 1Q 2020). The increase in margin was driven by higher revenue.
Is New 90 Day High Low • Mar 09New 90-day low: CN¥125The company is down 3.0% from its price of CN¥129 on 09 December 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥1.01 per share.
Reported Earnings • Mar 04Full year 2020 earnings released: EPS CN¥5.23 (vs CN¥0.69 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥8.43b (up 201% from FY 2019). Net income: CN¥2.08b (up CN¥1.80b from FY 2019). Profit margin: 25% (up from 9.9% in FY 2019). The increase in margin was driven by higher revenue.
Analyst Estimate Surprise Post Earnings • Mar 04Revenue misses expectationsRevenue missed analyst estimates by 6.2%. Over the next year, revenue is expected to shrink by 36% compared to a 57% growth forecast for the Biotechs industry in China.
Valuation Update With 7 Day Price Move • Jan 28Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥147, the stock is trading at a trailing P/E ratio of 21.6x, down from the previous P/E ratio of 26.2x. This compares to an average P/E of 64x in the Biotechs industry in China. Total returns to shareholders over the past year are 85%.
Is New 90 Day High Low • Jan 21New 90-day high: CN¥166The company is up 25% from its price of CN¥133 on 23 October 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥0.93 per share.
Valuation Update With 7 Day Price Move • Jan 11Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥148, the stock is trading at a trailing P/E ratio of 21.7x, up from the previous P/E ratio of 18.8x. This compares to an average P/E of 66x in the Biotechs industry in China. Total returns to shareholders over the past year are 117%.
Is New 90 Day High Low • Dec 18New 90-day low: CN¥127The company is down 10.0% from its price of CN¥142 on 18 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥1.51 per share.
Is New 90 Day High Low • Nov 17New 90-day low: CN¥132The company is down 7.0% from its price of CN¥141 on 19 August 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥1.33 per share.
Reported Earnings • Oct 28Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥2.71b, with earnings increasing by CN¥2.38b from the prior year. Total revenue was CN¥7.48b over the last 12 months, up 168% from the prior year.
Is New 90 Day High Low • Oct 23New 90-day low: CN¥133The company is down 12% from its price of CN¥151 on 24 July 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥1.22 per share.